Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13918097 | 0.87 | L3MBTL1 (0.53) | RXFP1KMT2AALDH1A1MEN1KDM4E | |
| SCHEMBL30666326 | 0.86 | RXFP1 (0.51) | RXFP1KMT2AALDH1A1MEN1KDM4E | |
| SCHEMBL15058686 | 0.86 | RXFP1 (0.51) | RXFP1KMT2AALDH1A1MEN1KDM4E | |
| SCHEMBL1167294 | 0.85 | KMT2A (0.53) | KMT2AALDH1A1MEN1KDM4ECYP1A2 | |
| SCHEMBL29444425 | 0.84 | ALDH1A1 (0.56) | RXFP1KMT2AALDH1A1MEN1KDM4E | |
| SCHEMBL4689570 | 0.84 | ALDH1A1 (0.56) | RXFP1KMT2AALDH1A1MEN1KDM4E | |
| SCHEMBL29902970 | 0.84 | KDM4E (0.51) | KMT2AALDH1A1MEN1KDM4EL3MBTL1 | |
| SCHEMBL11772465 | 0.84 | KDM4E (0.51) | KMT2AALDH1A1MEN1KDM4EL3MBTL1 | |
| SCHEMBL5621140 | 0.83 | KMT2A (0.50) | KMT2AALDH1A1MEN1KDM4ENPC1 | |
| SCHEMBL1167517 | 0.83 | ERCC5 (0.58) | KMT2AALDH1A1MEN1KDM4EPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030229073-A1 | Tricyclic compounds and method of treating herpes virus | BOOTH RICHARD JOHN (US) | 2003-12-11 | — | — | US | claimed |
| EP-1248777-A2 | TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY | WARNER-LAMBERT COMPANY (US) | 2002-10-16 | — | — | EP | claimed |
| WO-2001051479-A2 | TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY | WARNER-LAMBERT COMPANY (US) | 2001-07-19 | — | — | WO | claimed |
| US-12637436-B2 | Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2026-05-26 | — | — | US | disclosed |
| US-20250230147-A1 | LACTAMS AS CBL-B INHIBITORS | GENENTECH, INC. (US) | 2025-07-17 | — | — | US | disclosed |
| CN-119775241-A | 5-Hydroxy benzofuran derivative and preparation method thereof | 华东理工大学 | 2025-04-08 | — | — | CN | disclosed |
| US-20250011319-A1 | SUBSTITUTED 1H-PYRAZOLO [4,3-c] QUINOLINES, METHODS OF PREPARATION, AND USE THEREOF | LOMOND THERAPEUTICS, INC. | 2025-01-09 | — | — | US | disclosed |
| EP-4416146-A1 | SUBSTITUTED 1H-PYRAZOLO [4,3-C] QUINOLINES, METHODS OF PREPARATION, AND USE THEREOF | Lomond Therapeutics, Inc. (US) | 2024-08-21 | — | — | EP | disclosed |
| CN-118076605-A | Substituted 1H-pyrazolo [4,3-c ] quinolines, methods of preparation and uses thereof | 洛蒙治疗公司 | 2024-05-24 | — | — | CN | disclosed |
| EP-4288429-A1 | LACTAMS AS CBL-B INHIBITORS | Genentech, Inc. (US) | 2023-12-13 | — | — | EP | disclosed |
| CN-117088824-A | Preparation method of alpha-1, 3, 5-triazine thioketone compound | 浙江工业大学 | 2023-11-21 | — | — | CN | disclosed |
| US-20030229073-A1 | Tricyclic compounds and method of treating herpes virus | BOOTH RICHARD JOHN (US) | 2003-12-11 | — | — | US | disclosed |
| US-6544985-B2 | For therapy of acute and/or chronic neurological disorders such as psychosis, schizophrenia, Alzheimer's disease, cognitive disorders and memory deficits | HOFFMAN-LA ROCHE INC. | 2003-04-08 | — | — | US | disclosed |
| EP-1276739-A2 | HETEROCYCLES THAT ARE INHIBITORS OF IMPDH ENZYME | Bristol-Myers Squibb Company (US) | 2003-01-22 | — | — | EP | disclosed |
| US-20020193367-A1 | Dihydro-benzo [b] [1,4] diazepin-2-one derivatives | F. HOFFMAN-LA ROCHE AG A SWISS COMPANY (CH) | 2002-12-19 | — | — | US | disclosed |
| WO-2002083652-A1 | DIHYDRO-BENZO [b] [1, 4] DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II | F. HOFFMANN-LA ROCHE AG (CH) | 2002-10-24 | — | — | WO | disclosed |
| EP-1248777-A2 | TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY | WARNER-LAMBERT COMPANY (US) | 2002-10-16 | — | — | EP | disclosed |
| US-20020040022-A1 | Heterocycles that are inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY | 2002-04-04 | — | — | US | disclosed |
| WO-2001081340-A2 | HETEROCYCLES THAT ARE INHIBITORS OF IMPDH ENZYME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-11-01 | — | — | WO | disclosed |
| WO-2001051479-A2 | TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY | WARNER-LAMBERT COMPANY (US) | 2001-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040022-A1 | Heterocycles that are inhibitors of IMPDH enzyme | XDH, IMPDH1, IMPDH2 | RXFP1 2979/4885KMT2A 3646/4885ALDH1A1 155/4885 |
| US-20030229073-A1 | Tricyclic compounds and method of treating herpes virus | HDAC8, ZC3HAV1, ZCCHC8 | RXFP1 2716/4885KMT2A 412/4885ALDH1A1 4486/4885 |
| US-20250230147-A1 | LACTAMS AS CBL-B INHIBITORS | CBLB, CBL, CBLC | RXFP1 4411/4885KMT2A 1976/4885ALDH1A1 4354/4885 |
| US-20250011319-A1 | SUBSTITUTED 1H-PYRAZOLO [4,3-c] QUINOLINES, METHODS OF PREPARATION, AND USE THEREOF | FLT3, PDXK, PHKG1 | RXFP1 3823/4885KMT2A 863/4885ALDH1A1 2059/4885 |
| US-20020193367-A1 | Dihydro-benzo [b] [1,4] diazepin-2-one derivatives | CYP1B1, GRIN2B, BDKRB1 | RXFP1 421/4885KMT2A 1244/4885ALDH1A1 316/4885 |
| US-12637436-B2 | Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof | GRM3, GRM2, GRM1 | RXFP1 415/4885KMT2A 1325/4885ALDH1A1 3385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.